• OPEN AN ACCOUNT
Indian Indices
Nifty
25,461.00 55.70
(0.22%)
Sensex
83,432.89 193.42
( 0.23%)
Bank Nifty
57,031.90 239.95
( 0.42%)
Nifty IT
39,166.55 312.25
( 0.80%)
Global Indices
Nasdaq
44,849.54 344.11
(0.77%)
Dow Jones
6,300.35 51.93
(0.83%)
Hang Seng
39,792.23 6.33
(0.02%)
Nikkei 225
8,822.91 -0.29
(0.00%)
Forex
USD-INR
85.44 -0.20
(-0.23%)
EUR-INR
100.61 -0.32
(-0.32%)
GBP-INR
116.59 -0.52
(-0.45%)
JPY-INR
0.59 0.00
(-0.64%)

EQUITY - MARKET SCREENER

IndusInd Bank Ltd
Industry :  Banks - Private Sector
BSE Code
ISIN Demat
Book Value()
532187
INE095A01012
822.2006928
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
INDUSINDBK
25.24
66702.76
EPS(TTM)
Face Value()
Div & Yield %
33.92
10
0
 

Lupin gets USFDA nod for Loteprednol Etabonate Ophthalmic Gel
Jul 02,2025

The product is a generic equivalent of Lotemax SM Ophthalmic Gel, 0.38%, marketed by Bausch & Lomb Inc.

Lupin is the exclusive first-to-file applicant for this product and is eligible for 180 days of generic drug exclusivity. The product will be manufactured at Lupin’s Pithampur facility in India.

Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery.

According to IQVIA MAT data for May 2025, Loteprednol Etabonate Ophthalmic Gel, 0.38% (Reference Listed Drug: Lotemax® SM) had estimated annual sales of $29 million in the U.S.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company’s consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24.

The scrip rose 0.85% to Rs 1,978.05 on the BSE.